Furthermore, mechanistic exploration revealed that T+A@Glu‐NPs degraded the BRD4 protein, leading to the downregulation of Notch1 gene transcription and the inhibition of the Notch1 signaling pathway, thereby augmenting the therapeutic efficacy of glioma chemotherapy. Here, BRD4 is linked to central nervous system cancer.